2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - 353-355
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

454 Dual HDAC3/8 PROTAC degraders modulate enhancer acetylation and reveal a therapeutic vulnerability in activated B-cell–like diffuse large B-cell lymphoma

Michael Y. He, PhD, Yufeng Xiao, PhD2, Mehran Bakhtiari, MS3, Albert Santamaria-Martínez, PhD4, Justine Epiney5, Peiyi Zhang6, Ting Liu, PhD7, Wenxi Xu, PhD8, Davidson Zhao9, Anne Cairoli, MD10, David G. Brooks, PhD11, Elisa Oricchio12, Hansen He, PhD13, Guangrong Zheng, PhD14, Robert Kridel, MD15
1 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
2 University of Florida, Gainesville, Florida, United States
3 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
4 École Polytechnique Fédérale de Laussane, Lausanne, Switzerland, Swiss Cancer Center Le´man, Lausanne, Switzerland
5 CHUV-Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, École Polytechnique Fédérale de Laussane, Lausanne, Switzerland, Swiss Cancer Center Le´man, Lausanne, Switzerland
6 University of Florida, Gainesville, Florida, United States
7 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
8 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
9 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
10 CHUV-Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
11 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
12 École Polytechnique Fédérale de Laussane, Lausanne, Switzerland, Swiss Cancer Center Le´man, Lausanne, Switzerland
13 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
14 University of Florida, Gainesville, Florida, United States
15 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada

Background: Activated B-cell–like diffuse large B-cell lymphoma (ABC-DLBCL) remains difficult to cure despite advances in immunotherapy and antibody–drug conjugates. Epigenetic deregulation is a hallmark of DLBCL, yet pan-histone deacetylase (HDAC) inhibitors have shown limited clinical benefit, likely due to broad isoform activity and toxicity. HDAC3 regulates lymphoma-relevant repressive chromatin states, and HDAC8 has emerging roles in DLBCL biology. However, combined HDAC3/8 targeting has not been evaluated. We used selective proteolysis-targeting chimera (PROTAC) degraders as chemical probes and therapeutic leads to test whether dual HDAC3/8 degradation creates an actionable epigenetic vulnerability.

Methods: We analyzed HDAC3/8 expression in DLBCL tumors and cell lines and compared the first-generation dual HDAC3/8 PROTAC YX968 with single HDAC3 and HDAC8 PROTACs, catalytic inhibitors, and matched degradation-deficient negative controls. Transcriptional and chromatin mechanisms were examined by RNA-seq, H3K27ac ChIP-seq, flow cytometry, and rescue with the CREBBP/EP300 acetyltransferase inhibitor A-485. Medicinal chemistry optimization generated the second-generation dual degrader YX226, which was evaluated by degradation kinetics, microsomal stability, pharmacokinetics, global proteomics, and ternary complex assays. Therapeutic efficacy was assessed using xenografts, patient-derived organoids, primary human CD8+ T-cell assays, co-cultures, and combination testing.

Results: Concordantly high HDAC3/8 expression was enriched in ABC-DLBCL tumors, and ABC-DLBCL cell lines showed higher baseline HDAC3/8 protein abundance than the germinal center B-cell–like (GCB) subtype. YX968 preferentially killed ABC-DLBCL cells at sub-micromolar concentrations and was more potent than single HDAC3 or HDAC8 PROTACs. This effect was not reproduced by the degradation-deficient negative control despite HDAC3/8 inhibitory activity, demonstrating that degradation, rather than catalytic inhibition alone, drives the response. RNA-seq across YX968-treated ABC- and GCB-DLBCL cell models revealed an ABC-selective transcriptional program characterized by repression of cell-cycle, mitotic, and chromosome-organization genes coupled with induction of immune-response genes, especially major histocompatibility complex class II (MHC-II) antigen-presentation pathways. H3K27ac ChIP-seq showed broad YX968-induced H3K27ac gains preferentially shifted toward enhancers, and integrated RNA-seq/ChIP-seq linked enhancer acetylation gains to immune gene activation. A-485 reduced YX968-induced H3K27ac and partially rescued MHC-II upregulation in ABC-DLBCL cells, supporting enhancer acetylation as a functional mechanism.

Although potent, YX968 had poor metabolic stability. We therefore optimized the dual degrader scaffold and identified YX226 as a lead compound. YX226 induced rapid, low-nanomolar HDAC3/8 degradation, showed markedly improved microsomal stability, and achieved favorable in vivo exposure. Global proteomics confirmed selective HDAC3/8 depletion, sparing of other HDAC isoforms, and reduction of HDAC3-associated corepressor proteins NCOR1/NCOR2. Ternary complex assays showed that YX226 induced engagement of the von Hippel-Lindau (VHL) complex with HDAC3 or HDAC8, but not HDAC1 or HDAC2. YX226 preserved the functional activity of YX968, inducing apoptosis, cell-cycle arrest, H3K27ac induction, and MHC-I/II upregulation. In SU-DHL-2 xenografts, YX226 inhibited tumor growth (P < 0.0001), reduced endpoint tumor weight, and induced tumoral HDAC3/8 degradation without significant reduction of body weight. In patient-derived ABC/non-GCB DLBCL organoids, YX226 suppressed malignant B-cell proliferation and increased cleaved caspase-3. YX226 also activated primary human CD8+ T cells without overt toxicity and enhanced CD8+ T cell–mediated killing of DLBCL cells. Finally, focused combination screening identified the BCL-2 inhibitor venetoclax as the strongest partner, and enhanced activity by YX226–venetoclax was validated in ABC-DLBCL cell and xenograft models.

Conclusion: These findings establish dual HDAC3/8 degradation as a chemical biology–guided therapeutic strategy for ABC-DLBCL. By linking selective HDAC3/8 degradation to enhancer acetylation remodeling, immune activation, and apoptotic vulnerability, and by advancing YX226 as a metabolically optimized lead, this work supports further development of dual HDAC3/8 PROTACs for aggressive B-cell lymphomas.

Michael Y. He, PhD: No relevant conflicts of interest to declare.